Alterity Therapeutics Limited (ASX:ATH) Share Price Falls 4.46% as Stock Trades Within Daily Range

Anjali Anand

13 August 2026 09:32 PM AEST

Alterity Therapeutics Limited (ASX:ATH) Share Price Falls 4.46% as Stock Trades Within Daily Range

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Alterity Therapeutics Limited (ASX:ATH) shares closed lower at $0.535 after declining 4.464% during the session.
The stock traded within a daily range of $0.520 to $0.565.
Trading Volume reached 309,861 shares during the session.
Market capitalisation stood at $122.06M based on the latest provided figures.
The share price remained within its 52-week range of $0.350 to $0.785.

Overview

Alterity Therapeutics Limited (ASX:ATH) is listed on the Australian Securities Exchange and operates within the Pharmaceuticals, Biotechnology & Life Sciences industry group. This article provides an educational summary of the company’s share price activity and available market statistics based on the latest provided trading information. It focuses on price movement, trading activity, Market Capitalisation and historical trading range without providing Investment recommendations.

Share Price Movement

Shares of Alterity Therapeutics Limited (ASX:ATH) closed at $0.535, representing a decline of $0.025 or 4.464% compared with the previous close of $0.560. During the trading session, the stock moved between an intraday high of $0.565 and an intraday low of $0.520.

The difference between the day’s highest and lowest trading prices reflects the range within which Market Participants traded the stock during the session. Daily share price movements can occur due to changes in buying and selling activity, market conditions and company-specific factors. ((ASX:ATH) Historical Stock Price Data">StockAnalysis)

At the latest available price, the stock was positioned above its 52-week low of $0.350 and below its 52-week high of $0.785. The 52-week range provides a historical reference point showing the broader price movement observed over the previous year.

Trading Volume and Market Capitalisation

Alterity Therapeutics Limited recorded trading volume of 309,861 shares during the session. Trading volume represents the number of shares exchanged between buyers and sellers and is commonly monitored alongside daily price movements to understand the level of market participation.

The stock’s average volume was recorded at 186,376 shares, indicating that the latest session’s trading activity was above the stated average volume level. Changes in trading volume can provide information about the level of activity surrounding a listed security.

The company’s market capitalisation was $122.06M based on the latest provided share price and available market data. Market capitalisation represents the total Market Value of a company’s Issued Shares and is calculated using the share price and shares outstanding.

Share Information and Trading Range

Alterity Therapeutics Limited has 217,976,240 shares on issue, with the ordinary fully paid share structure listed under its share information. The company was listed on 28 March 2000.

The bid and offer range was recorded between $0.535 and $0.545, reflecting the available buying and selling price levels during the trading session. The day range of $0.520 to $0.565 highlights the movement experienced by the stock within the single trading period.

Understanding these daily trading indicators can help readers assess how a stock performed during a particular session while considering broader historical information such as the 52-week trading range.

Industry Group and Market Context

Alterity Therapeutics Limited is classified under the Pharmaceuticals, Biotechnology & Life Sciences industry group. Companies within this category generally operate in areas associated with pharmaceutical research, biotechnology development and life sciences activities.

The share price movement of individual companies can vary based on company-specific developments, market participation and broader conditions affecting listed securities. A single Trading session represents only one point in time and does not represent the complete performance history of a company.

Conclusion

In summary, Alterity Therapeutics Limited (ASX:ATH) shares closed at $0.535 after recording a decline of 4.464% during the latest trading session. The stock traded between $0.520 and $0.565, with volume of 309,861 shares and a market capitalisation of $122.06M. The available trading statistics, including the 52-week range and share information, provide an overview of the company’s market position at the reported time. This article is intended for educational purposes and does not represent financial advice or a recommendation regarding the stock.

Frequently Asked Questions (FAQs)

FAQs

Q: What was the closing share price of Alterity Therapeutics Limited (ASX:ATH)?

A:Alterity Therapeutics Limited (ASX:ATH) closed at $0.535 based on the latest provided market data.

Q: How much did ATH shares decline during the session?

A:The share price declined by $0.025, representing a decrease of 4.464% from the previous close of $0.560.

Q: What was the trading volume for Alterity Therapeutics Limited?

A:The trading volume for the session was 309,861 shares.

Q: What is the market capitalisation of Alterity Therapeutics Limited?

A:The market capitalisation was recorded at $122.06M based on the provided data.

Q: What was the 52-week trading range for ASX:ATH?

A:The 52-week trading range was between $0.350 and $0.785.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.